Zai Lab (NASDAQ:ZLAB) Director Richard Gaynor Acquires 1,228 Shares of Stock

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Director Richard Gaynor bought 1,228 shares of the firm’s stock in a transaction on Tuesday, November 10th. The stock was bought at an average price of $27.19 per share, with a total value of $33,389.32. Following the completion of the purchase, the director owned 81,965 shares of the company’s stock, valued at $2,228,628.35. This trade represents a 1.52% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Zai Lab Stock Down 5.5%

Shares of NASDAQ:ZLAB traded down $1.44 during trading on Friday, hitting $24.60. 1,224,327 shares of the company traded hands, compared to its average volume of 900,098. The stock has a market capitalization of $3.08 billion, a price-to-earnings ratio of -13.74 and a beta of 0.77. The business’s fifty day moving average is $24.66 and its 200-day moving average is $21.22. Zai Lab Limited Unsponsored ADR has a one year low of $15.96 and a one year high of $29.02.

Zai Lab (NASDAQ:ZLAB) last announced its quarterly earnings results on Thursday, November 5th. The company reported ($0.41) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.18. Zai Lab had a negative return on equity of 31.15% and a negative net margin of 44.91%. The business had revenue of $108.21 million for the quarter, compared to analysts’ expectations of $107.90 million. On average, analysts forecast that Zai Lab Limited Unsponsored ADR will post -2.19 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on ZLAB shares. Citigroup raised their target price on Zai Lab from $44.00 to $45.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Cantor Fitzgerald restated an “overweight” rating on shares of Zai Lab in a research report on Tuesday, October 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zai Lab in a report on Tuesday, October 27th. Finally, Wall Street Zen raised shares of Zai Lab from a “sell” rating to a “hold” rating in a report on Saturday, September 26th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $37.25.

Hedge Funds Weigh In On Zai Lab

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Nantahala Capital Management LLC raised its stake in Zai Lab by 65.0% during the 3rd quarter. Nantahala Capital Management LLC now owns 330,000 shares of the company’s stock valued at $8,692,000 after acquiring an additional 130,000 shares in the last quarter. Nan Fung Trinity HK Ltd. grew its stake in shares of Zai Lab by 106.9% in the third quarter. Nan Fung Trinity HK Ltd. now owns 293,966 shares of the company’s stock worth $7,743,000 after purchasing an additional 151,883 shares in the last quarter. Alps Advisors Inc. grew its stake in shares of Zai Lab by 34.9% in the third quarter. Alps Advisors Inc. now owns 148,993 shares of the company’s stock worth $3,924,000 after purchasing an additional 38,562 shares in the last quarter. Seven Fleet Capital Management LP grew its stake in shares of Zai Lab by 74.7% in the second quarter. Seven Fleet Capital Management LP now owns 136,016 shares of the company’s stock worth $2,584,000 after purchasing an additional 58,158 shares in the last quarter. Finally, Headlands Technologies LLC increased its holdings in shares of Zai Lab by 142.0% during the second quarter. Headlands Technologies LLC now owns 68,010 shares of the company’s stock valued at $1,292,000 after purchasing an additional 39,901 shares during the period. 41.65% of the stock is owned by institutional investors.

Zai Lab Company Profile

Zai Lab is a biopharmaceutical company that discovers, develops and commercializes medicines for patients with serious diseases. Its research and development programs focus on oncology, immunology, neuroscience and infectious diseases. Founded in 2014 by biopharmaceutical executive Samantha Du, the company is headquartered in Shanghai and operates in China and the United States. It advances its own drug candidates and works with international partners to develop and bring therapies to market. Zai Lab’s portfolio includes medicines and development programs for cancers and other conditions, including therapies introduced through licensing and collaboration agreements.